These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070 [TBL] [Abstract][Full Text] [Related]
50. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions. Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370 [TBL] [Abstract][Full Text] [Related]
51. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. Lombardi F; Belmonti S; Quiros-Roldan E; Latini A; Castagna A; D'Ettorre G; Gagliardini R; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S; J Antimicrob Chemother; 2017 Jul; 72(7):2055-2059. PubMed ID: 28333353 [TBL] [Abstract][Full Text] [Related]
52. High prevalence of PI resistance in patients failing second-line ART in Vietnam. Thao VP; Quang VM; Day JN; Chinh NT; Shikuma CM; Farrar J; Van Vinh Chau N; Thwaites GE; Dunstan SJ; Le T J Antimicrob Chemother; 2016 Mar; 71(3):762-74. PubMed ID: 26661398 [TBL] [Abstract][Full Text] [Related]
53. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ; N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505 [TBL] [Abstract][Full Text] [Related]
54. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. Alteri C; Artese A; Beheydt G; Santoro MM; Costa G; Parrotta L; Bertoli A; Gori C; Orchi N; Girardi E; Antinori A; Alcaro S; d'Arminio Monforte A; Theys K; Vandamme AM; Ceccherini-Silberstein F; Svicher V; Perno CF J Antimicrob Chemother; 2013 Oct; 68(10):2205-9. PubMed ID: 23687186 [TBL] [Abstract][Full Text] [Related]
55. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain]. Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386 [TBL] [Abstract][Full Text] [Related]
56. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H; Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249 [TBL] [Abstract][Full Text] [Related]
57. Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from São Paulo, Brazil. Santos AMRD; Martins AP; Juliato D; de Miranda ÉJFP; Lopes GISL; Brígido LFM; Vidal JE Int J STD AIDS; 2020 Sep; 31(10):967-975. PubMed ID: 32698729 [TBL] [Abstract][Full Text] [Related]
58. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. Youle M J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281 [TBL] [Abstract][Full Text] [Related]
59. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation. Sahloff EG; Duggan JM Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788 [TBL] [Abstract][Full Text] [Related]
60. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]